ReviewAnnals of biomedical engineering2026
Camptothecin Nanoformulations: Recent Advances in Preparation, Bioactivities, and Clinical Perspectives.
Review in Annals of biomedical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Polymeric Nano Drug Delivery Systems for Overcoming Tumor Microenvironment-Mediated Drug Resistance.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Camptothecin (CPT) is a naturally occurring alkaloid recognized for its broad spectrum of biological activities, including potent anticancer, anti-inflammatory, antibacterial, and antioxidant effects. Its clinical application, however, is restricted by inherent limitations such as poor aqueous solubility, instability of the pharmacologically active lactone ring, and severe systemic toxicity. To overcome these challenges, a variety of nanotechnology-based delivery systems, including liposomes, polymeric nanoparticles, solid lipid nanoparticles (SLNs), and micelles, have been developed to enhance the physicochemical stability and pharmacokinetic profiles of CPT. Despite considerable progress, a comprehensive review integrating recent advances in CPT nanoformulation strategies, preparation techniques, and therapeutic applications has been lacking in the past two years. This review systematically examines the design principles, delivery platforms, and fabrication methods for CPT-loaded nanoformulations and critically analyzes how these approaches improve bioavailability and therapeutic efficacy. In addition, this review integrates recent advances in CPT nanomedicines, summarizes the current patent landscape and clinical trial developments, and highlights how formulation strategies are designed to facilitate clinical translation. By comparing diverse nanoformulations strategies and identifying design principles that have shown translational promise, this work uniquely bridges material innovation with therapeutic optimization, providing a critical insight into how nanotechnology can address the pharmacological barriers of CPT and inspire next-generation drug delivery systems.
Indexed as
Identifiers
41528374What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.